Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Rovanersen (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; First in man
- Acronyms PRECISION-HD1
- Sponsors WaVe life Sciences
- 16 Jun 2021 Status changed from active, no longer recruiting to discontinued.
- 07 May 2021 This trial has been discontinued in Denmark according to European Clinical Trials Database record.
- 03 May 2021 This trial has been Discontinued in France, according to European Clinical Trials Database record.